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Abstract 
Lapatinib is a tyrosine kinase inhibitor used for the treatment of breast cancer. Paracetamol is an 
analgesic commonly applied to patients with mild or moderate pain and fever. Cancer patients are 
polymedicated, which involves high risk of drug interactions during therapy. The aimof the study was to 
assess the interaction between lapatinib and paracetamol in rats. The rats were divided into three groups 
of eight animals in each. One group received lapatinib + paracetamol (IL+PA), another group received 
lapatinib (IIL), whereas the last group received paracetamol (IIIPA). A single dose of lapatinib (100 mg/kg 
b.w.) and paracetamol (100 mg/ kg b.w.) was administered orally. Plasma concentrations of lapatinib, 
paracetamol and its metabolites – glucuronide and sulphate, were measured with the validated HPLC-
MS/MS method and HPLC-UV method, respectively. The pharmacokinetic parameters of both drugs were 
calculated using non-compartmental methods. The co-administration of lapatinib and paracetamol 
increased the area under the plasma concentration-time curve (AUC) and the maximum concentration 
(Cmax) of lapatinib by 239.6% (p = 0.0030) and 184% (p = 0.0011), respectively. Lapatinib decreased the 
paracetamol AUC0-∞ by 48.8% and Cmax by 55.7%. In the IL+PA group the Cmax of paracetamol 
glucuronide was reduced, whereas the Cmax of paracetamol sulphate was higher than in the IIIPA group. 
Paracetamol significantly affected the enhanced plasma exposure of lapatinib. Additionally, lapatinib 
reduced the concentrations of paracetamol. The co-administration of lapatinib decreased the 
paracetamol glucuronidation but increased the sulphation. The findings of this study may be of clinical 
relevance to patients requiring analgesic therapy. 
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Summary
Lapatinib is a tyrosine kinase inhibitor used for the treatment of breast cancer. Paracetamol is an analgesic commonly applied to
patients with mild or moderate pain and fever. Cancer patients are polymedicated, which involves high risk of drug interactions
during therapy. The aim of the study was to assess the interaction between lapatinib and paracetamol in rats. The rats were divided
into three groups of eight animals in each. One group received lapatinib + paracetamol (IL + PA), another group received lapatinib
(IIL), whereas the last group received paracetamol (IIIPA). A single dose of lapatinib (100 mg/kg b.w.) and paracetamol (100 mg/
kg b.w.) was administered orally. Plasma concentrations of lapatinib, paracetamol and its metabolites – glucuronide and sulphate,
were measured with the validated HPLC-MS/MSmethod and HPLC-UVmethod, respectively. The pharmacokinetic parameters
of both drugs were calculated using non-compartmental methods. The co-administration of lapatinib and paracetamol increased
the area under the plasma concentration-time curve (AUC) and the maximum concentration (Cmax) of lapatinib by 239.6% (p =
0.0030) and 184% (p = 0.0011), respectively. Lapatinib decreased the paracetamol AUC0-∞ by 48.8% and Cmax by 55.7%. In the
IL + PA group the Cmax of paracetamol glucuronide was reduced, whereas the Cmax of paracetamol sulphate was higher than in the
IIIPA group. Paracetamol significantly affected the enhanced plasma exposure of lapatinib. Additionally, lapatinib reduced the
concentrations of paracetamol. The co-administration of lapatinib decreased the paracetamol glucuronidation but increased the
sulphation. The findings of this study may be of clinical relevance to patients requiring analgesic therapy.
Keywords Lapatinib .Paracetamol .Paracetamolglucuronideandparacetamolsulphatepharmacokinetics .Drug-drug interaction
Introduction
Pain is a frequent symptom associated with cancer. Therefore,
analgesic drugs are often administered to oncological patients
[1]. Paracetamol effectively relieves pain due to selective
inhibition of cyclooxygenase-2 (COX-2) and −3 (COX-3) in
the central nervous system by interfering with descending
serotoninergic pathways and, to some extent, by blocking
the activity of pain mediators (bradykinine, substance P).
Therapeutic doses are safe and tolerated well, but excessive
intake of the drug may cause hepatotoxicity. Paracetamol is
essentially metabolised in the liver. It is chiefly transformed by
glucuronidation (40–60%) and sulphation (20–46%). In
consequence, pharmacologically inactive metabolites are
formed, while less than 10% is oxidised to a toxic
metabolite, i.e. N-acetyl-p-benzoquinone imine (NAPQI)
[2]. Many authors proved that paracetamol is a substrate of
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ABC transmembrane transporter – P-glycoprotein (P-gp).
Many studies also revealed that paracetamol could modulate
the P-gp activity. However, it is still unclear whether it is a
potent inhibitor or inducer of this protein, and what factors
may influence the direction of P-gp modulation by
paracetamol.
Lapatinib is a small-molecule tyrosine kinase inhibitor
(TKI), targeted at human epidermal growth factor receptor
type 2 (HER2, ErbB2). It is used in combination with cape-
citabine, trastuzumab and aromatase inhibitors to treat breast
cancer in HER2-positive women [3–5]. The metabolism of
lapatinib is mediated mainly by CYP3A4 and CYP3A5, and
to a minor extent – by CYP2C19 and CYP2C8 isoenzymes.
Additionally, lapatinib was identified as a substrate of P-gp
and BCRP (breast cancer resistance protein). It also inhibits
the activity of P-gp, BCRP and OATP1B1. However, the clin-
ical relevance of inhibition of the latter two transporters has
not been elucidated. Some TKIs may inhibit UDP-
glucuronyltransferase (UGT) and cause drug-drug interac-
tions. In vitro and in vivo studies confirmed that nilotinib
and erlotinib inhibited UGT1A, whereas gefitinib inhibited
UGT1A1, 1A7, 1A9 and 2B7. There is not much data
concerning the influence of lapatinib on the UGT activity.
Zhan et al. [6] found that lapatinib inhibited glucuronidation
of SN-38 (active metabolite of irinotecan) in human micro-
somes and recombinant UGT1A1 proteins. The quantitative
prediction of drug-drug interaction risk indicates its clinical
significance. Although Liu et al. [7] showed that lapatinib was
a weak inhibitor of paracetamol glucuronidation, the in vtiro
model of their study may underestimate inhibition of
glucuronidation observed in vivo. Therefore, it is important
to check the possible in vivo effect of lapatinib on para-
cetamol metabolism. The aim of this study was to inves-
tigate the influence of orally administered lapatinib on the
pharmacokinetics of paracetamol and its glucuronidation and
sulphation in rats. In addition, changes in the pharmacokinetic




Lapatinib (CAS number 231277–92-9), paracetamol (CAS
number 103–90-2), methanol, acetonitrile, formic acid,
perchloric acid, theophyllinum, ammonium formate, and di-
methyl sulfoxide were purchased from Sigma-Aldrich
(Poznań, Poland). Erlotinib (CAS number 183321–74-6),
paracetamol glucuronide and paracetamol sulphate were pur-
chased from LGC Standards (Łomianki, Poland). Water used
in the mobile phase was deionised, distilled and filtered
through a Millipore system (Direct Q3, Millipore, USA)
before use. Lapatinib (Tyverb®, batch number Y68Y) was
purchased from Novartis Polska Sp. z o.o., (Warsaw,
Poland). Paracetamol (Pedicetamol, batch number K003)
was purchased from Sequoia sp. z o.o., (Warsaw, Poland).
Animals
The experimental protocol for this study was reviewed and
approved by the Local Ethics Committee. All procedures were
performed in accordance with the European Union regulations
concerning the handling and use of laboratory animals. The
study was based on the required minimum number of animals
and observation time in order to obtain consistent data. Adult
male Wistar rats (weight 420–505 g) were used in the study.
The animals were maintained under standard breeding condi-
tions with a 12/12 h light-dark cycle (lights on at 06.00, lights
off at 18.00) at constant room temperature (23 ± 2 °C), relative
humidity (55% ± 10%) and given ad libitum access to food
and water. The animals were allowed to acclimatise for a week
before the beginning of the experiments. The rats were divid-
ed into three groups. One group received lapatinib and para-
cetamol (IL + PA), another group received lapatinib (IIL),
whereas the last group received paracetamol (IIIPA).
Lapatinib (100 mg/kg b.w. [8]) was dissolved in 1 mL
DMSO (dimethyl sulfoxide) and administered directly into
the animals’ stomachs using a gastric probe. In order to make
sure that the animals received the entire dose of the drug, 1 mL
of DMSO was then administered to rinse the probe. 80 μL of
blood was collected from each rat by cutting off a piece of his
tail. The blood samples were collected into heparinised test
tubes at the following time points: 0, 15′, 30′, 1 h, 2 h, 3 h, 4 h,
6 h, 8 h, 12 h, 24 h. Paracetamol was administrated at a dose of
100 mg per kg of body weight [9] to the IL + PA and IIIPA
groups. Blood samples (approximately 0.3 mL) for paraceta-
mol analysis were collected before and 5, 15, 30, 60, 90, 120,
180, 240, 360 and 480 min after the drug administration. The
blood samples were transferred into heparinised tubes and
they were centrifuged at 2880 g for 10 min at 4 °C.
HPLC-UV assay
The concentrations of paracetamol, paracetamol glucuronide
and paracetamol sulphate were assayed using the HPLCmeth-
od (high-performance liquid chromatography) with ultraviolet
(UV) detection [10]. Separation was achieved by isocratic
elution of the mobile phase, sodium sulphate 0.05 M pH 2.2
(adjusted with 85% orthophosphoric acid) – acetonitrile (93:7,
v/v), at a flow rate of 1.5 mL/min through an ODS Hypersil®
C18 column (150 mm × 4.6 mm, 5.0 μm particle size)
(Thermo Electron Corporation®, Waltham, MA, USA). The
total time of analysis for each run was 10 min. The column
temperature was maintained at 25 °C, the UV detection wave-
length was set at 261 nm, and the injection volume was 50μL.
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The validation was performed according to the guidelines of
the European Medicines Agency (EMA) concerning valida-
tion of bioanalytical methods. The lower limit of quantifica-
tion (LLOQ) for paracetamol was 0.25 μg/mL, whereas for
paracetamol glucuronide and paracetamol sulphate it was
1 μg/mL. Intra- and inter-day precision and accuracy of the
LLOQ, low quality control (0.2, 2 and 2 μg/mL), medium
quality control (30, 30 and 25 μg/mL), and high quality con-
trol (50, 50 and 40 μg/mL) were well within the acceptable
limit of 11% coefficient of variation (CV%) and 10% of bias
(% bias) for paracetamol, paracetamol glucuronide and para-
cetamol sulphate. The calibration curve for paracetamol was
linear, within the range of 0.1–65 μg/mL (r = 0.995), for para-
cetamol glucuronide within the range of 1–60 μg/mL (r =
0.994) and for paracetamol sulphate within the range of 1–
50 μg/mL (r = 0.998). 20 μL of the internal standard solution
and 200 μL of 6% perchloric acid were added to 100 μL of the
rat plasma. The samples were shaken for 30 s and then they
were centrifuged for 10 min at 5000 g. About 100 μL of the
resulting supernatants was transferred into glass inserts and a
volume of 50 μL was injected onto HPLC column.
HPLC-MS/MS assay
Lapatinib in the plasma samples was quantified using a high
performance liquid chromatograph 1260 Infinity (Agilent
Technologies, Santa Clara, CA, USA) combined with a triple
quadrupole mass spectrometer 4000 QTRAP (Sciex,
Framingham,MA, USA). Chromatographic separation was per-
formed on a Kinetex C18 column (50 × 4.6 mm, 2.6 μm,
Phenomenex, Torrance, CA, USA). The column temperature
and injection volume were set at 35 °C and 10 μL, respectively.
The mobile phase comprised 0.1% formic acid in water with
5 mM ammonium formate (eluent A) and acetonitrile with 10%
phaseA (eluent B). The flow rate wasmaintained at 700μL/min
and the gradient elution was as follows: 0–2 min, 95% A; 2–4
linear min from 95% to 5% A; 4–5 min, 5% A; 5–6 min linear
from 5% to 95% A; 6–10 min, 95% A. The mass spectrometer
operated in the multiple reaction monitoring mode. Two transi-
tions for lapatinib and erlotinib (IS) were monitored: m/z
581.1→ 365.1 (quantifier transition) and 581.1→ 350.1 (qual-
ifier transition) for lapatinib, and m/z 394.1→ 278.1 (quantifier
transition) and 394.1→ 304.1 (qualifier transition) for IS.
An aliquot of the rat plasma (20 μL) was mixed with 50μL
of IS solution (100 ng/mL) and 930 μL of methanol and then
vortexed for 30 s. As a result, a total dilution factor of 50 was
obtained. After centrifugation at 10,000 g (10 min), the super-
natant was transferred into amber glass HPLC vials. The val-
idation was performed according to the guidelines of EMA
concerning validation of bioanalytical methods. Different vol-
umes of the lapatinib standard solution with 50 μL IS (c =
100 ng/L) were mixed in a total volume of 1.0 mLmethanol to
prepare calibration samples. The resulting correlation
coefficient r > 0.995 ranged from 0.25 μg/L to 150 μg/L.
The lower quantification limit was 0.25 μg/L. Quality control
(QC) samples at four concentration levels (0.25; 0.5; 75;
125 μg/L) were obtained by spiking rat plasma samples with
known quantities of lapatinib. The validation proved high pre-
cision (CV < 15%) and accuracy (%bias≤13%) of the
methodology.
Pharmacokinetic evaluation
The pharmacokinetic parameters were estimated with the non-
compartmental method, using Phoenix® WinNonlin® 7.0
software (Certara L.P.). kel – elimination rate constant;
AUC0-t – area under the plasma concentration-time curve
from zero to the time of the last measurable concentration;
AUC0-∞ – area under the plasma concentration-time curve
from zero to infinity; t0.5 – elimination half-life; Cl/F – clear-
ance; Vd/F – volume of distribution; Cmax –maximum plasma
concentration; tmax – time necessary to reach the maximum
concentration; MRT0-t – mean residence time; AUMC0-t –
area under the first moment curve.
Statistical analysis
The traits were tested for departure from normality using the
Shapiro-Wilk test. The traits which did not show significant
deviation from normality were subject to the heterogeneity of
variance test, followed by pooled (heterogeneity of variance
test p-value>0.05) or Satterthwaite (heterogeneity of the vari-
ance test p-value <0.05) t-tests to verify the significance of
differences between the IL + PA and IIL or IL + PA and IIIPA.
Differences between the IL + PA and IIL or IL + PA and IIIPA in
the characteristics which showed significant deviation from
normality were tested with the Kruskal-Wallis test. The anal-
ysis was performed using capability t-test and npar1way pro-
cedures of SAS (SAS Institute Inc. 2002–2012. The SAS
System for Windows version 9.4. Cary, NC, USA).
Results
All the data were expressed as the mean value ± standard de-
viation (SD). The groups of rats did not differ significantly in
the body mass. There was high intersubject variability between
the groups, as reflected by the coefficient of variation (CV%).
The influence of paracetamol
on the pharmacokinetics of lapatinib
Figure 1 shows the mean plasma concentration versus time
profiles. Table 1 shows the associated pharmacokinetic
parameters.
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The administration of paracetamol considerably increased
lapatinib plasma concentrations. The mean Cmax (p = 0.0011)
and AUC0 −∞ (p = 0.0065)in the lapatinib with paracetamol
group were higher than in the lapatinib group. The increase in
Cmax by 284.0% as well as AUC0 − ∞ by 491.3% in the
combination of lapatinib and paracetamol indicated that
paracetamol significantly increased the bioavailability of
lapatinib.
The influence of lapatinib
on the pharmacokinetics of paracetamol,
paracetamol glucuronide and paracetamol
sulphate
The mean arithmetic plasma concentrations of paracetamol,
paracetamol glucuronide and paracetamol sulphate in the
IL + PA and IIIPA groups are shown in Figs. 2, 3 and 4
respectively.
In comparison with the IIIPA group the exposure to para-
cetamol in the IL + PA group decreased, as evidenced by lower
AUC0-t (p < 0.0001), AUC0-∞ (p = 0.0004), Cmax (p = 0.0030)
andAUMC0-t (p = 0.0023). There were also significant chang-
es in the exposure of paracetamol metabolites between both
groups. In the IL + PA group the Cmax, AUC0-t and AUC0-∞ of
paracetamol glucuronide were reduced by 24%, 26%, 29%,
respectively, whereas the Cmax, AUC0-t and AUC0-∞ of para-
cetamol sulphate increased significantly by about 84%, 61%,
58%, respectively, as compared with the IIIPA group (Table 2).
Discussion
Patients with metastatic breast cancer often suffer from pain at
every stage of the disease. Paracetamol is one of the most
common antipyretic and analgesic drugs. When paracetamol
therapy follows the product characteristics, the risk of adverse
effects is low. The most serious adverse reaction associated
with paracetamol is hepatotoxic effect of one of its metabo-
lites, i.e. N-acetyl-p-benzoquinone imine (NAPQI) [11].
Hepatotoxicity can be observed if there is insufficient amount
of glutathione [12], e.g. when the drug has been overdosed or
when the patient has consumed alcohol [13]. It is very likely
that paracetamol and lapatinib will be applied simultaneously.
Therefore, the possible interaction between the drugs may
affect their pharmacokinetics.
The main goal of our study was to evaluate the influence of
paracetamol on the pharmacokinetic parameters of lapatinib.
We observed that the Cmax of lapatinib and the exposure to the
drug increased significantly in the IL + PA group. These chang-
es may be explained by increased inhibition of P-glycoprotein
by paracetamol in the intestine. There were similar results in a
study on rabbits receiving another TKI – erlotinib [14].
Studies on animals also revealed sex-dependent interactions
with other drugs (paracetamol, ibuprofen, diclofenac,
mefenamic acid) [15–17]. Paracetamol reduced male mice’s
exposure to sunitinib by 29%, but did not affect the concen-
tration of this TKI in female mice. However, it reduced both
male and female mice’s exposure to the drug in their liver (by
15% and 9%, respectively), kidneys (by 15% and 20%) and
brain (47% and 50%) [15]. Tan et al. [17] observed that the
male mice which received paracetamol had 2.2 times higher
liver sunitinib concentrations and 1.4 times greater kidney
concentrations than the control group. These concentrations
were significantly lower in the group of female mice.
According to the authors, these changes may have been
caused by sex-dependent differences in the activity of
metabolising enzymes and proteins participating in the trans-
port of drugs.
The aim of the second part of the study was to investigate
the effect of lapatinib on the pharmacokinetics of paracetamol.
There were statistically significant differences in the Cmax,


























Fig. 1 Lapatinib (L) plasma
concentration–time profiles in rats
receiving lapatinib + paracetamol
(IL + PA) and lapatinib (IIL)
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paracetamol between the groups. The Cmax, AUC0-t and AUC0
−∞ of paracetamol in the rats which received paracetamol and
lapatinib were respectively about 60.5%, 56.8% and 48.8%
lower than in the control group. The study also revealed a
considerable increase in the Vd/F and Cl/F values of paracet-
amol (351.5% and 147.4%, respectively) and a slight increase
(12.1%) in the MRT0-t of the drug.
There were also changes in the PK of paracetamol metab-
olites. The Cmax, AUC0-t and AUC0−∞ values of paracetamol
glucoronide decreased by about 24.4%, 25.5% and 28.6% in
the group of animals receiving both drugs, respectively. On
the contrary, the Cmax, AUC0-t, and AUC0−∞ of paracetamol
sulphate increased significantly (by 81.1%, 61.4%, 5.4%, re-
spectively) in the animals from the IL + PA group.
The abovementioned alterations in the PK of paracetamol
and its main metabolites may have been caused by the inhibi-
tion of paracetamol biotransformation by lapatinib. Midgley
et al. [18] observed a similar effect of lapatinib on the PK of
Table 1 Plasma pharmacokinetic
parameters of lapatinib following
a single p.o. dose of lapatinib of
100 mg/kg
Pharmacokinetic parametersa IL + PA
M ± SD (CV%)
IIL
M ± SD (CV%)
IL + PA vs. IIL
p-value
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a AUC0-t. area under the plasma concentration-time curve from zero to the time of the last measurable concen-
tration; Cmax. maximum plasma concentration; tmax. Time to the first occurrence of Cmax; t0.5. half-life in elim-
ination phase; Cl/F. clearance (Cl); Vd/F. volume of distribution; AUMC0-t. area under the first moment curve
from zero to the time of the last measurable concentration; MRT0-t. mean residence time;





























Fig. 2 Paracetamol (PA) plasma
concentration–time profiles in rats
receiving paracetamol (IIIPA) and
lapatinib + paracetamol (IL + PA)
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irinotecan. They conducted a phase I clinical trial on the phar-
macokinetics of lapatinib administered together with leucovorin,
irinotecan and 5-fluorouracil and they observed that the AUC of
the active irinotecan metabolite – SN-38 increased by about
40%. The authors suggested that the greater exposure to SN-
38 may have been attributed to the inhibition of membrane
transporters (OATP1B1, P-gp and BCRP) as well as metabolic
enzymes - CYP3A4 and UGT1A1 by lapatinib [6]. Zhang et al.
[6] confirmed that the inhibition of SN-38 glucuronidation was
caused by considerable reduction of the UGT1A1 activity by
lapatinib. The researchers also observed non-competitive
UGT1A7 inhibition and mixed UGT1A4 inhibition [6].
Glucuronyl transferase UGT1A1 is one of the main en-
zymes responsible for glucuronidation of paracetamol [19,
20]. UGT1A1 isoform plays an important role in the metabo-
lism of paracetamol, especially in case of high plasma con-
centration of the drug [20]. The inhibition of glucuronidation
may redirect biotransformation of the drug to different path-
ways, such as increased conjugation with sulphuric acid, ox-
idation and formation of NAPQI. It is well known that
lapatinib is a strong competitive inhibitor of glucuronyl trans-
ferase UGT1A1 [6]. However, to date there have been no
available in vivo data concerning the effect of lapatinib on
the paracetamol PK. Liu et al. [7] conducted an in vitro study
and proved that other TKIs – sorafenib, dasatinib and imatin-
ib, inhibited paracetamol glucuronidation in human liver mi-
crosomes. Similarly, axitinib, erlotinib, gefitinib, lapatinib,
nilotinib and vandetanib exhibited a slight inhibitory effect
against UGTs [7]. Importantly, the same authors emphasised
the fact that particular caution should be taken when extrapo-
lating in vitro studies to clinical situations. The study on the
sunitinib and paracetamol interaction in rabbits proved that
concomitant administration of the drugs (25 mg p.o., 35 mg/
kg b.w. i.v., respectively), contributed to lower exposure and
faster clearance of paracetamol [21]. Furthermore, the same
authors observed that another TKI – erlotinib, modified the
metabolism of paracetamol, reducing its glucuronidation and
intensifying its sulphation. Our study revealed changes in
paracetamol metabolism which are consistent with other au-
































Fig. 3 Paracetamol glucuronide
(PA-G) concentration–time
profiles in rats receiving
paracetamol (IIIPA) and lapatinib

























Fig. 4 Paracetamol sulphate
(PA-S) concentration–time
profiles in rats receiving
paracetamol (IIIPA) and
lapatinib + paracetamol (IL + PA)
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Table 2 Plasma pharmacokinetic
parameters of paracetamol,
paracetamol glucuronide and
paracetamol sulphate following a
single p.o. dose of paracetamol of
100 mg/kg
Pharmacokinetic parametersa IIIPA
M ± SD (CV%)
IL + PA
M ± SD (CV%)
IL + PA vs. IIIPA
p-value
paracetamol
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a AUC0-t. area under the plasma concentration-time curve from zero to the time of the last measurable concen-
tration; Cmax. maximum plasma concentration; tmax. Time to the first occurrence of Cmax; t0.5. half-life in elim-
ination phase; Cl. clearance (Cl); Vd/kg. volume of distribution per kilogram; AUMC0-t. area under the first
moment curve from zero to the time of the last measurable concentration; MRT0-t. mean residence time;
b t-test; c Satterthwaite test; d Kruskal-Wallis test; e paracetamol glucuronide/paracetamol ratio; f paracetamol
sulphate/paracetamol ratio
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glucuronidation by lapatinib on the animal model. Therefore,
these observations should be verified on patients.
As was mentioned above, the alterations of metabolic path-
ways of paracetamol, especially the inhibition of
glucuronidation, may lead to excessive synthesis of NAPQI,
which is the most toxic metabolite [22] responsible for liver
damage after the drug overdose. Ridruejo et al. [23] described
the case of a 51-year-old female patient who was treated with
imatinib administered at a dose of 400 mg/d due to chronic
myelogenous leukaemia (CML). The overproduction of
NAPQI, due to the inhibition of glucuronidation by imatinib,
may have caused paracetamol-induced hepatotoxicity in the
patient. Therefore, lapatinib may also exaggerate the hepato-
toxicity of paracetamol. This hypothesis was supported by
studies conducted by Moy et al. [24], who noted an isolated
increase in the alanine aminotransferase (ALT) value, which
was more than 3 times greater than the upper limit of normal
values (ULN) in 3–5% of patients subjected to lapatinib ther-
apy. The ULNwas exceeded 5–20 times in 1.6% of the patients
treated with lapatinib, whereas it caused hyperbilirubinemia
and severe liver damage in 0.2% of the patients. Concomitant
use of lapatinib and other cytotoxic drugs increases their hep-
atotoxicity due to the accumulation of the drugs in hepatocytes.
Manov et al. [25] and Pingli et al. [22] observed that the co-
administration of P-gp inhibitors (verapamil, quinidine, keto-
conazole and chrysin) increased the concentration and total
exposure to paracetamol. This observation suggests that para-
cetamol is also a P-gp substrate. Thus, its toxicity may in-
crease when it is administered with lapatinib, which is a strong
inhibitor of this transporter.
Conclusions
Due to the fact that the study proved higher concentration and
exposure to lapatinib, there is also higher risk of lapatinib
hepatotoxicity during a long-term combination therapy. It is
especially important, because paracetamol is widely available
as an over-the-counter drug. Patients may take paracetamol
without consulting a physician, which may result in more
frequent occurrence of adverse effects of both drugs.
Patients should be carefully monitored to recognise symptoms
of hepatotoxicity early. On the other hand, the reduced expo-
sure to paracetamol and a considerable increase in clearance of
the drug suggest that the analgesic activity decreases when
paracetamol is administered together with lapatinib. The an-
algesic effect could be achieved by applying a higher dose of
the drug or by reducing the dosage interval.
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